EP4501404A3 — Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
Assigned to Nippon Shinyaku Co Ltd · Expires 2025-05-07 · 1y expired
What this patent protects
The present invention relates to a solid preparation comprising: 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; and D-mannitol having a specific surface area larger than 0.2 m<sup>2</sup>/g and smaller than 0.7 m<sup>2…
USPTO Abstract
The present invention relates to a solid preparation comprising: 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; and D-mannitol having a specific surface area larger than 0.2 m<sup>2</sup>/g and smaller than 0.7 m<sup>2</sup>/g.
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.